Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract

Journal of Surgical Oncology

Volumn 89, Issue 3, 2005, Pages 151-160

  Rorstad, Otto ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Carcinoid heart disease; Carcinoid tumor; Gastrointestinal neoplasms; Malignant carcinoid syndrome; Prognosis

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CHROMOGRANIN A; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER GROWTH; CARCINOID; CARCINOID SYNDROME; GASTROINTESTINAL TUMOR; HEART DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; TUMOR LOCALIZATION; TUMOR VOLUME;

CARCINOID HEART DISEASE; CARCINOID TUMOR; CHROMOGRANIN A; CHROMOGRANINS; GASTROINTESTINAL NEOPLASMS; HUMANS; HYDROXYINDOLEACETIC ACID; LYMPHATIC METASTASIS; MALIGNANT CARCINOID SYNDROME; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 14644392193     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20179     Document Type: Review

References (84)

1. Oberndorfer S: Karzinoide tumoren des dunndarms. Frankf Z Pathol 1907;1:425-432.
2. Marks C: Carcinoid tumors. A clinicopathologic study. Boston: GK Hall; 1979.
3. Pearson CM, Fitzgerald PJ: Carcinoid tumors. A reemphasis of their malignant nature: Review of 140 cases. Cancer 1949;2: 1005-1026.
4. Williams ED, Sandler M: The classification of carcinoid tumours. Lancet 1963;1:238-239.
5. Pearse AGE: The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryonic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969;17:303-313.
6. Rindi G, Leiter AB, Kopin AS, et al.: The "normal" endocrine cell of the gut. Changing concepts and new evidences. Ann NY Acad Sci 2004;1014:1-12.
7. Soga J, Yakuwa Y, Osaka M: A classification of problems regarding gut endocrinomas (carcinoids and relevant neoplasms). J Exp Clin Cancer Res 1999;18:5-12.
8. Soga J: Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res 2003;22:517-530.
9. Solcia E, Klöppel G, Sobin LH: Histological typing of endocrine tumours. WHO International Histological Classification of Tumours. Berlin: Springer; 2000.
10. Feldman JM: Carcinoid tumors and the carcinoid syndrome. Curr Probl Surg 1989;26:835-885.
11. Soga J, Yakuwa Y, Osaka M: Carcinoid syndrome: A statistical evaluation of 748 reported cases. J Exp Clin Cancer Res 1999;18:133-141.
12. Travis WD, Colby TV, Corrin B, et al.: Histological typing of lung and pleural tumours, 3rd edition. Berlin: Springer; 1999.
13. Sobin LH, Wittekind C: TNM classification of malignant tumors. 6th edition. New York: Wiley-Liss; 2002.
14. American Joint Committee on Cancer: AJCC cancer staging handbook, 6th edition. New York: Springer; 2002.
15. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959.
16. Shebani KO, Souba WW, Finkelstein DM, et al.: Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999;229:815-821.
17. McDermott EWM, Guduric B, Brennan MF: Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994;81:1007-1009.
18. Sjöblom SM: Clinical presentation and prognosis of gastrointestinal carcinoid tumours. Scand J Gastroenterol 1988;23:779-787.
19. Greenberg RS, Baumgarten DA, Clark WS, et al.: Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors. Cancer 1987;60:2476-2483.
20. Zeitels J, Naunheim K, Kaplan EL, et al.: Carcinoid tumors. A 37-year experience. Arch Surg 1982;117:732-737.
21. Thompson GB, van Heerden JA, Martin JK, Jr., et al.: Carcinoid tumors of the gastrointestinal tract: Presentation, management, and prognosis. Surgery 1985;98:1054-1062.
22. Strodel WE, Talpos G, Eckhauser F, et al.: Surgical therapy for small-bowel carcinoid tumors. Arch Surg 1983;118:391-397.
23. Moertel CG: Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1503-1522.
24. Soga J: Carcinoids of the small intestine: A statistical evaluation of 1102 cases collected from the literature. J Exp Clin Cancer Res 1997;16:353-363.
25. Makridis C, Öberg K, Juhlin C, et al.: Surgical treatment of midgut carcinoid tumors. World J Surg 1990;14:377-385.
26. Anderson JR, Wilson BG: Carcinoid tumours of the appendix. Br J Surg 1985;72:545-546.
27. Glasser CM, Bhagavan BS: Carcinoid tumors of the appendix. Arch Pathol Lab Med 1980;104:272-275.
28. Moertel CG, Weiland LH, Nagorney DM, et al.: Carcinoid tumors of the appendix: Treatment and prognosis. N Engl J Med 1987;317:1699-1701.
29. Roggo A, Wood WC, Ottinger LW: Carcinoid tumors of the appendix. Ann Surg 1993;217:385-390.
30. Ballantyne GH, Savoca PE, Flannery JT, et al.: Incidence and mortality of carcinoids of the colon. Data from the Connecticut Tumor Registry. Cancer 1992;69:2400-2405.
31. Berardi RS: Carcinoid tumors of the colon (exclusive of the rectum): Review of the literature. Dis Colon Rectum 1972;15:383-391.
32. Burke M, Shepherd N, Mann CV: Carcinoid tumours of the rectum and anus. Br J Surg 1987;74:358-361.
33. Federspiel BH, Burke AP, Sobin LH, et al.: Rectal and colonic carcinoids. A clinicopathologic study of 84 cases. Cancer 1990;65:135-140.
34. Jetmore AB, Ray JE, Gathright JB, Jr., et al.: Rectal carcinoids: The most frequent carcinoid tumor. Dis Colon Rectum 1992;35:717-725.
35. Orloff MJ: Carcinoid tumors of the rectum. Cancer 1971;28:175-180.
36. Koura AN, Giacco GG, Curley SA, et al.: Carcinoid tumors of the rectum: Effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 1997;79:1294-1298.
37. Naunheim KS, Zeitels J, Kaplan EL, et al.: Rectal carcinoid tumors-treatment and prognosis. Surgery 1983;94:670-676.
38. Soga J: Carcinoids of the rectum: An evaluation of 1271 reported cases. Surg Today 1997;27:112-119.
39. Spread C, Berkel H, Jewell L, et al.: Colon carcinoid tumors. A population-based study. Dis Colon Rectum 1994;37:482-491.
40. Soga J: Carcinoids of the colon and ileocecal region: A statistical evaluation of 363 cases collected from the literature. J Exp Clin Cancer Res 1998;17:139-148.
41. Janson ET, Holmberg L, Stridsberg M, et al.: Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-690.
42. Soga J: Esophageal endocrinomas, an extremely rare tumor: A statistical comparative evaluation of 28 ordinary carcinoids and 72 atypical variants. J Exp Clin Cancer Res 1998;17:47-57.
43. Rindi G, Luinetti O, Cornaggia M, et al.: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study. Gastroenterology 1993;104:994-1006.
44. Granberg D, Wilander E, Stridsberg M, et al.: Clinical symptoms, hormone profiles, treatment and prognosis in patients with gastric carcinoids. Gut 1998;43:223-228.
45. Soga J: Gastric carcinoids: A statistical evaluation of 1094 cases collected from the literature. Surg Today 1997;27:892-901.
46. Rappel S, Altendorf-Hofmann A, Stolte M: Prognosis of gastric carcinoid tumors. Digestion 1995;56:455-462.
47. Soga J: Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases. J Exp Clin Cancer Res 2003;22:349-363.
48. Capella C, Riva C, Rindi G, et al.: Histopathology, hormone products, and clinicopathological profile of endocrine tumors of the upper small intestine: A study of 44 cases. Endocr Pathol 1991;2:92-110.
49. Rindi G, Azzoni C, La Rosa S, et al.: ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis. Gastroenterology 1999;116:532-542.
50. Soga J: Statistical evaluation of 2001 carcinoid cases with metastases, collected from the literature: A comparative study between ordinary carcinoids and atypical varieties. J Exp Clin Cancer Res 1998;17:3-12.
51. Shimizu T, Tanaka S, Haruma K, et al.: Growth characteristics of rectal carcinoid tumors. Oncology 2000;59:229-237.
52. Sökmensüer C, Gedikoglu G, Uzunalimoglu B: Importance of proliferation markers in gastrointestinal carcinoid tumors: A clinicopathologic study. Hepatogastroenterology 2001;48:720-723.
53. Onogawa S, Tanaka S, Oka S, et al.: Clinical significance of angiogenesis in rectal carcinoid tumors. Oncol Rep 2002;9:489-494.
54. Moyana TN, Xiang J, Senthilselvan A, et al.: The spectrum of neuroendocrine differentiation among gastrointestinal carcinoids. Importance of histological grading, MIB-1, p53, and bcl-2 immunoreactivity. Arch Pathol Lab Med 2000;124:570-576.
55. Li CC, Hirokawa M, Qian ZR, et al.: Expression of E-cadherin, β-catenin, and Ki-67 in goblet cell carcinoids of the appendix: An immunohistochemical study with clinical correlation. Endocr Pathol 2002;13:47-58.
56. von Herbay A, Sieg B, Schürmann G, et al.: Proliferative activity of neuroendocrine tumours of the gastroenteropancreatic endocrine system: DNA flow cytometric and immunohistological investigations. Gut 1991;32:949-953.
57. Chaudhry A, Öberg K, Wilander E: A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 1992;13:27-35.
58. Amarapurkar AD, Davies A, Ramage JK, et al.: Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: Relevance to prognosis. Eur J Gastroenterol Hepatol 2003;15:139-143.
59. Kawahara M, Kammori M, Kanauchi H, et al.: Immunohistochemical prognostic indicators of gastrointestinal carcinoid tumours. Eur J Surg Oncol 2002;28:140-146.
60. Cheng JY, Sheu LF, Meng CL, et al.: Expression of p53 protein in colorectal carcinoids. Arch Surg 1996;131:67-70.
61. Tomita T: p53 and proliferating cell nuclear antigen in endocrine tumors of pancreas and intestinal carcinoids. Pathology 1997;29:147-153.
62. Lohmann DR, Funk A, Niedermeyer HP, et al.: Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Arch B Cell Pathol Incl Mol Pathol 1993;64:293-296.
63. Wang DG, Johnston CF, Buchanan KD: Oncogene expression in gastroenteropancreatic neuroendocrine tumors. Implications for pathogenesis. Cancer 1997;80:668-675.
64. Van Gompel JJ, Sippel RS, Warner TF, et al.: Gastrointestinal carcinoid tumors: Factors that predict outcome. World J Surg 2004;28:387-392.
65. Norheim I, Öberg K, Theodorsson-Norheim E, et al.: Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987;206:115-125.
66. Makridis C, Ekbom A, Bring J, et al.: Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. Surgery 1997;122:1075-1082.
67. Lundin L, Norheim I, Landelius J, et al.: Carcinoid heart disease: Relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 1988;77:264-269.
68. Pellikka PA, Tajik AJ, Khandheria BK, et al.: Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-1196.
69. Denney WD, Kemp WE, Jr., Anthony LB, et al.: Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol 1998;32:1017-1022.
70. Westberg G, Wängberg B, Ahlman H, et al.: Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 2001;88:865-872.
71. Møller JE, Connolly HM, Rubin J, et al.: Factors associated with progression of carcinoid heart disease. N Engl J Med 2003;348:1005-1015.
72. Zuetenhorst JM, Bonfrer JMGM, Korse CM, et al.: Carcinoid heart disease. The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-β and fibroblast growth factor. Cancer 2003;97:1609-1615.
73. Lundin L, Öberg K, Landelius J, et al.: Plasmal atrial natriuretic peptide in carcinoid heart disease. Am J Cardiol 1989;63:969-972.
74. Zuetenhorst JM, Korse CM, Bonfrer JMG, et al.: Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 2004;90:2073-2079.
75. Robiolio PA, Rigolin VH, Wilson JS, et al.: Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-795.
76. Agranovich AL, Anderson GH, Manji M, et al.: Carcinoid tumor of the gastrointestinal tract: Prognostic factors and disease outcome. J Surg Oncol 1991;47:45-52.
77. Taupenot L, Harper KL, O'Connor DT: The chromogranin-secretogranin family. N Engl J Med 2003;348:1134-1149.
78. Hofland LJ, Lamberts SWJ: The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47.
79. Kvols LK, Reubi JC, Horisberger U, et al.: The presence of somatostatin receptors in malignant neuroendocrine tumor tissues predicts responsiveness to octreotide. Yale J Biol Med 1992;65:505-518.
80. Janson ET, Stridsberg M, Gobl A, et al.: Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998;58:2375-2378.
81. 1]Octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994;131:577-581.
82. Nilsson O, Kölby L, Wängberg B, et al.: Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998;77:632-637.
83. Anthony LB, Martin W, Delbeke D, et al.: Somatostatin receptor imaging: Predictive and prognostic considerations. Digestion 1996;57(Suppl 1):50-53.
84. Quaedvlieg PFHJ, Visser O, Lamers CBHW, et al.: Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001;12:1295-1300.